Compare Quest Diagnostics Inc (DGX) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Monster Beverage Corp — how do they compare? Quest Diagnostics Inc trades at $237.6 (market cap $26.21B), while Monster Beverage Corp trades at $45.59 (market cap $89.20B). The key difference: Monster Beverage Corp is far larger — about 3.4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| DGX | MNST | |
|---|---|---|
Market Cap | $26.21B | $89.20B |
Sector | Health | Consumer Staples |
52-Week High | $238.50 | $49.97 |
52-Week Low | $173.49 | $30.86 |
Enterprise Value | $31.97B | $87.49B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Monster Beverage (MNST) trades at $45.53, down 0.35% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $8.29B and net income of $1.91B, maintaining robust profit margins above 23%. Recent Q2 2026 results exceeded expectations with $0.60 EPS versus $0.59 expected, driven by international growth. The stock completed a 2-for-1 split on August 11, 2026.
MNST presents a mixed outlook with strong earnings momentum and international expansion offset by premium valuation concerns. The stock trades at 42.16x P/E, above sector averages, while analyst consensus targets $51.14 suggest 12% upside. Key risks include competitive pressures in energy drinks and valuation sensitivity to growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
